CEL-SCI Corp. | Mutual Funds
Mutual Funds that own CEL-SCI Corp.
Vanguard Total Stock Market Index Fund
215,407
0.9%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
195,328
0.81%
19,800
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
59,386
0.25%
0
0%
07/31/2018
iShares Micro Cap ETF
38,508
0.16%
0
0.01%
09/06/2018
Vanguard Institutional Total Stock Market Index Fund
37,674
0.16%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
25,753
0.11%
0
0%
07/31/2018
16,000
0.07%
0
0.11%
07/31/2017
5,999
0.03%
0
0.05%
09/05/2018
iShares Core S&P Total US Stock Market ETF
3,184
0.01%
0
0%
09/06/2018
Vanguard Balanced Index Fund
1,845
0.01%
0
0%
07/31/2018
| Address |
8229 Boone Boulevard
Vienna Virginia 22182
United States
|
|
Employees
|
- |
| Website |
http://www.cel-sci.com |
| Updated |
07/08/2019 |
| CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. |
